Search tips
Search criteria 


Logo of bmjThe BMJ
BMJ. 1996 August 3; 313(7052): 275–283.
PMCID: PMC2351717

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.9M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Gerard K. Cost-utility in practice: a policy maker's guide to the state of the art. Health Policy. 1992 Jul;21(3):249–279. [PubMed]
  • Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med. 1992 Feb 1;116(3):238–244. [PubMed]
  • Adams ME, McCall NT, Gray DT, Orza MJ, Chalmers TC. Economic analysis in randomized control trials. Med Care. 1992 Mar;30(3):231–243. [PubMed]
  • Jefferson T, Demicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Econ. 1994 Jan-Feb;3(1):25–37. [PubMed]
  • Williams A. The cost-benefit approach. Br Med Bull. 1974 Sep;30(3):252–256. [PubMed]
  • Drummond M, Brandt A, Luce B, Rovira J. Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care. 1993 Winter;9(1):26–36. [PubMed]
  • Clemens K, Townsend R, Luscombe F, Mauskopf J, Osterhaus J, Bobula J. Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America. Pharmacoeconomics. 1995 Aug;8(2):169–174. [PubMed]
  • Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med. 1994 Sep 8;331(10):669–670. [PubMed]
  • Schulman K, Sulmasy DP, Roney D. Ethics, economics, and the publication policies of major medical journals. JAMA. 1994 Jul 13;272(2):154–156. [PubMed]
  • Jefferson T, Demicheli V. Are guidelines for peer-reviewing economic evaluations necessary? A survey of current editorial practice. Health Econ. 1995 Sep-Oct;4(5):383–388. [PubMed]
  • Smith R. Conflict of interest and the BMJ. BMJ. 1994 Jan 1;308(6920):4–5. [PMC free article] [PubMed]
  • Jefferson T, Demicheli V, Entwistle V. Assessing quality of economic submissions to the BMJ. BMJ. 1995 Aug 5;311(7001):393–394. [PMC free article] [PubMed]
  • Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making. 1989 Apr-Jun;9(2):142–149. [PubMed]
  • Mugford M, Kingston J, Chalmers I. Reducing the incidence of infection after caesarean section: implications of prophylaxis with antibiotics for hospital resources. BMJ. 1989 Oct 21;299(6706):1003–1006. [PMC free article] [PubMed]
  • Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics. 1995 Jun;7(6):490–502. [PubMed]
  • Avorn J. Benefit and cost analysis in geriatric care. Turning age discrimination into health policy. N Engl J Med. 1984 May 17;310(20):1294–1301. [PubMed]
  • Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995 Jun;14(2):171–189. [PubMed]
  • Wald NJ. Couple screening for cystic fibrosis. Lancet. 1991 Nov 23;338(8778):1318–1319. [PubMed]
  • Drummond MF, Bloom BS, Carrin G, Hillman AL, Hutchings HC, Knill-Jones RP, de Pouvourville G, Torfs K. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care. 1992 Fall;8(4):671–682. [PubMed]
  • Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1991 May 1;114(9):798–802. [PubMed]
  • Oster G, Epstein AM. Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine. JAMA. 1987 Nov 6;258(17):2381–2387. [PubMed]
  • Fordham R, Field DJ, Hodges S, Normand C, Mason E, Burton P, Yates J, Male S. Cost of neonatal care across a regional health authority. J Public Health Med. 1992 Jun;14(2):127–130. [PubMed]
  • Egberts J. Estimated costs of different treatments of the respiratory distress syndrome in a large cohort of preterm infants of less than 30 weeks of gestation. Biol Neonate. 1992;61 (Suppl 1):59–65. [PubMed]
  • Parsonage M, Neuburger H. Discounting and health benefits. Health Econ. 1992 Apr;1(1):71–76. [PubMed]
  • Cairns J. Discounting and health benefits: another perspective. Health Econ. 1992 Apr;1(1):76–79. [PubMed]
  • Briggs A, Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ. 1995 Sep-Oct;4(5):355–371. [PubMed]
  • Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994 Mar-Apr;3(2):95–104. [PubMed]
  • O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care. 1994 Feb;32(2):150–163. [PubMed]
  • Wakker P, Klaassen MP. Confidence intervals for cost/effectiveness ratios. Health Econ. 1995 Sep-Oct;4(5):373–381. [PubMed]
  • Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med. 1993 Jul;37(1):33–40. [PubMed]
  • Birch S, Gafni A. Cost-effectiveness ratios: in a league of their own. Health Policy. 1994 May;28(2):133–141. [PubMed]
  • Johannesson M. The relationship between cost-effectiveness analysis and cost-benefit analysis. Soc Sci Med. 1995 Aug;41(4):483–489. [PubMed]

Articles from The BMJ are provided here courtesy of BMJ Publishing Group